This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Prometheus Biosciences Future Growth
Future criteria checks 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Prometheus Biosciences.
Key information
12.1%
Earnings growth rate
14.9%
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | 70.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 13 Jun 2023 |
Recent future growth updates
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 89 | -293 | -194 | -446 | 9 |
| 12/31/2024 | 7 | -232 | -173 | -302 | 10 |
| 12/31/2023 | 3 | -193 | N/A | -208 | 6 |
| 3/31/2023 | 4 | -151 | -136 | -133 | N/A |
| 12/31/2022 | 7 | -142 | -126 | -123 | N/A |
| 9/30/2022 | 7 | -133 | -107 | -104 | N/A |
| 6/30/2022 | 7 | -123 | -100 | -97 | N/A |
| 3/31/2022 | 6 | -108 | -76 | -74 | N/A |
| 12/31/2021 | 3 | -90 | -65 | -64 | N/A |
| 9/30/2021 | 3 | -69 | -48 | -47 | N/A |
| 6/30/2021 | 2 | -50 | -35 | -34 | N/A |
| 3/31/2021 | 2 | -38 | -42 | -42 | N/A |
| 12/31/2020 | 1 | -31 | -28 | -28 | N/A |
| 12/31/2019 | 1 | -17 | -20 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RXDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RXDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RXDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RXDX's revenue (70.2% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: RXDX's revenue (70.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RXDX's Return on Equity is forecast to be high in 3 years time